Bristol-Myers Squibb Company (BMY) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong margins ⢠High leverage ⢠Intangible-heavy assets BMY shows strong profitability and dividend coverage, but heavy leverage and a balance sheet dominated by intangibles temper the investment case despite only moderate valuation.
Price Behavior
Key Price Behavior Insights: ⢠Failed breakout ⢠Support rebound ⢠Overhead resistance Support Level: $56.50-$57.00 Resistance Level: $58.00-$59.50 Over the last month, BMY finished slightly higher but remained choppy, with a failed breakout in the high-$50s and a rebound from mid-$54 support that is constructive but still capped by $58-$59.5 resistance.
Sentiment & News
Key News Insights: ⢠Growth traction ⢠Pipeline catalysts ⢠Income support Bristol Myers Squibb is being watched as a value-and-income stock, with investor focus split between attractive yield and potential undervaluation versus patent-cliff risk and encouraging growth/pipeline momentum.
AI Summary
BMY should now be viewed less as a pure patent-cliff value trap and more as a pipeline-replacement story, but the stock likely won't re-rate until Breyanzi/Camzyos/Reblozyl and other new assets clearly outgrow legacy erosion while free cash flow continues to cover the dividend and keep leverage manageable.
Description
Bristol-Myers Squibb is a global biopharmaceutical company that researches, develops, licenses, manufactures and markets medicines across oncology, hematology, cardiovascular, immunology, fibrosis, neuroscience and infectious disease. Its commercial portfolio includes oral and biologic therapies for cancer, cardiovascular and immune-mediated conditions, with widely used products such as Eliquis and Opdivo, and it sells through wholesalers, pharmacies, hospitals and government channels. Founded in 1887, the company is headquartered in New York, New York.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 9 | Feb 16 | BMY | Bristol-Myers Squibb Company | Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days. | Closed | -0.1% |
| Dec 23 | Dec 30 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb (BMY) benefits from 17% Q3 portfolio growth, upcoming FDA review and clinical data catalysts, strong operational turnaround with positive earnings and cash flow, and sustained 17% stock gain over 21 days with technical momentum. Its diversified oncology portfolio and dividend appeal underpin a strong near-term growth case. | Closed | -0.1% |
| Dec 4 | Dec 11 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb shows compelling near-term upside with strong Q3 revenue and raised guidance, notable clinical/regulatory catalysts (FDA Fast Track, Phase 3 trials), substantial debt reduction, and technical breakout signaling positive momentum. | Closed | -1.4% |